On September 27, 2012, Onyx Pharmaceuticals, Inc. and Bayer Healthcare issued a press release reporting that the Food and Drug Administration, or FDA, had approved Bayer's StivargaŽ (regorafenib) tablets for treatment of patients with metastatic colorectal cancer. The press release dated September 27, 2012, titled "Bayer's StivargaŽ (regorafenib) Tablets Approved by the U.S. Food and Drug Administration for the Treatment of Metastatic Colorectal Cancer" is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

(d) Exhibits

Exhibit
Number                                  Description

99.1        Press Release titled "Bayer's StivargaŽ (regorafenib) Tablets
            Approved by the U.S. Food and Drug Administration for the Treatment
            of Metastatic Colorectal Cancer" dated September 27, 2012.